Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.26.4 (
RNase H
)
2,751
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Sex-determining region Y (SRY)-box protein 2 (
SOX2
) plays a critical role in stem cell maintenance and carcinogenesis. In addition to its function as a minor-groove DNA binding transcription factor, our previous study showed that
SOX2
also acts as a RNA binding protein. In current study, we first showed that
SOX2
displayed high affinity toward the mRNA encoding S100A14 in BFTC905 and that depletion of
SOX2
resulted in a decrease of S100A14 mRNA and protein level. To characterize the RNA binding sequence recognized by
SOX2
, oligomer-directed
RNase H
digestion was coupled to the cross-linking before immunoprecipitation assay to demonstrate that
SOX2
preferentially binds to the 3'-UTR of the S100A14 mRNA. Using EGFP-S100A14 3'-UTR reporters and mobility shift assay, we identified that the binding sequence on the 3'-UTR of the S100A14 mRNA exhibits a stem-loop structure. Together, our data indicates that
SOX2
enhances S100A14 expression by binding to the 3'-UTR of the S100A14 mRNA. Functionally, depletion of
SOX2
increases growth and mobility of BFTC905. Knock-down of S100A14 in BFTC905 also leads to an increase in the number of the cells in the S phase and higher mobility, suggesting that
SOX2
suppresses cell growth and mobility through promoting the expression of S100A14. Together, our experimental evidence indicates that
SOX2
is capable of exerting its cellular functions by functioning as an RNA binding protein in post-transcriptional regulation.
...
PMID:SOX2 suppresses the mobility of urothelial carcinoma by promoting the expression of S100A14. 2895 11